Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim W Rattay

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Annals of Clinical and Translational Neurology|April 5, 2021
Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegiaChristoph Kessler, Lina M Serna-Higuita, Tim W Rattay, et al.
Neurobiology of Disease|February 28, 2016
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizinMatteo Santoro, Walter Maetzler, Petros Stathakos, et al.
Plos One|March 4, 2016
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body DementiaWalter Maetzler, Willy Deleersnijder, Valérie Hanssens, et al.
Annals of Clinical and Translational Neurology|February 16, 2022
Characteristics of serum neurofilament light chain as a biomarker in hereditary spastic paraplegia type 4Christoph Kessler, Lina Maria Serna-Higuita, Carlo Wilke, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 14, 2018
Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-UpFlorian Härtig, Marlene Ross, Nele Maria Dammeier, et al.
Scientific Reports|September 16, 2020
Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (VLCFA) in genetically confirmed X-AdrenoleukodystrophyTim W Rattay, Maren Rautenberg, Anne S Söhn, et al.
Neurology|June 19, 2016
Uniparental disomy of chromosome 16 unmasks recessive mutations of FA2H/SPG35 in 4 familiesAnne S Soehn, Tim W Rattay, Stefanie Beck-Wödl, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 3, 2017
Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profilesStefanie Lerche, Claudia Schulte, Karin Srulijes, et al.
Journal of Neurology|October 27, 2020
PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot studyKathrin Gonsior, Gabriele Anna Kaucher, Patrik Pelz, et al.
BMC Neurology|August 23, 2023
Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES)Anna Hofmann, Corinna Blum, Constanze Single, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Annals of Clinical and Translational Neurology|April 5, 2021
Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegiaChristoph Kessler, Lina M Serna-Higuita, Tim W Rattay, et al.
Neurobiology of Disease|February 28, 2016
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizinMatteo Santoro, Walter Maetzler, Petros Stathakos, et al.
Plos One|March 4, 2016
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body DementiaWalter Maetzler, Willy Deleersnijder, Valérie Hanssens, et al.
Annals of Clinical and Translational Neurology|February 16, 2022
Characteristics of serum neurofilament light chain as a biomarker in hereditary spastic paraplegia type 4Christoph Kessler, Lina Maria Serna-Higuita, Carlo Wilke, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 14, 2018
Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-UpFlorian Härtig, Marlene Ross, Nele Maria Dammeier, et al.
Scientific Reports|September 16, 2020
Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (VLCFA) in genetically confirmed X-AdrenoleukodystrophyTim W Rattay, Maren Rautenberg, Anne S Söhn, et al.
Neurology|June 19, 2016
Uniparental disomy of chromosome 16 unmasks recessive mutations of FA2H/SPG35 in 4 familiesAnne S Soehn, Tim W Rattay, Stefanie Beck-Wödl, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 3, 2017
Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profilesStefanie Lerche, Claudia Schulte, Karin Srulijes, et al.
Journal of Neurology|October 27, 2020
PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot studyKathrin Gonsior, Gabriele Anna Kaucher, Patrik Pelz, et al.
BMC Neurology|August 23, 2023
Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES)Anna Hofmann, Corinna Blum, Constanze Single, et al.
Pageof 5